Abstract
Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET. © 2012 Carranza et al.
Author supplied keywords
Cite
CITATION STYLE
Carranza, M. A., Snyder, M. R., Elble, R. J., Boutzoukas, A. E., & Zesiewicz, T. A. (2012). Methodological issues in clinical drug development for essential tremor. Tremor and Other Hyperkinetic Movements. Center for Digital Research and Scholarship. https://doi.org/10.5334/TOHM.116
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
